Board Approval Details
The Board of Directors approved the allotment of 38,71,854 fully paid-up equity shares of face value ₹10 each at an issue price of ₹40 per share (including premium of ₹30 per share). The total consideration amounts to ₹15,48,74,160. The allotment was made on a preferential basis through private placement to shareholders of Sushodha Institute of Gastroenterology Private Limited (SIGPL) for consideration other than cash, specifically on a share swap basis.
Capital Structure Impact
Consequent to this allotment, the company's paid-up equity capital has increased from ₹48,02,18,570 (consisting of 4,80,21,857 equity shares) to ₹51,89,37,110 (consisting of 5,18,93,711 equity shares).
Share Characteristics
The newly allotted equity shares will rank pari-passu with existing equity shares in all respects. The shares will be subject to lock-in provisions as specified under Chapter VII of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
Regulatory Background and Approvals
The preferential issuance was previously approved by shareholders through postal ballot dated 13th August 2026. In-principle approval was received from BSE Limited vide Letter No. LOD/PREF/KS/FIP/920/2026-27 dated October 12, 2026.
Allottee Details
The allotment was made to 47 allottees, all categorized as Non-Promoters. The list includes individuals such as J K Pradeepkumar (1,328,124 shares), B K Anilkumar (591,129 shares), and entities like AKB Enterprises (101,241 shares). The complete list is provided in Annexure A.
Meeting Details
The Board meeting commenced at 3:30 PM and concluded at 5:30 PM on October 24, 2026.
Next Steps
The company will make application to stock exchanges for listing and trading approval for the newly allotted shares in due course. The information is also available on the company website at https://www.arvayahealth.com.